Kornimate/medical-research-clean huggingface dataset:
multimodal investigation of post covid-19 in females

Conditions: Post COVID-19; Cognitive Dysfunction

Summary: the purpose of this study is to investigate the effects of transcutaneous vagus nerve stimulation (t-vns) on long covid symptoms in females and to identify factors influencing susceptibility and recovery-particularly in the cognitive domain, as over 80% of long-haulers experience "brain fog".

long covid is a post-viral illness estimated to affect 10-30% of covid-19 patients. post-covid symptoms can last for months and affect multiple organs. major risk factors of long covid include the female sex and pre-existing anxiety/depression. because women already have higher rates of anxiety/depression, the combined risks could exacerbate their susceptibility. based on the rationale that long covid symptoms significantly overlap with functions of the vagus nerve, which serves as a conduit between the brain and body, the investigators propose to use non-invasive transcutaneous vagus nerve stimulation (t-vns) as a novel treatment for long covid in 20 female participants. this pilot study will utilize a holistic approach by integrating neuromodulation, neuroimaging, genetics, blood biomarkers, behavioral assessments, and wearable technology to examine the effects of vns therapy on post covid-19 symptoms and to identify factors that influence susceptibility and recovery, particularly in the cognitive domain, as over 80% of long-haulers report experiencing "brain fog" (i.e., cognitive disruptions).

Eligibility criteria:
inclusion criteria: * biologically female at birth and at time of enrollment * at least 18 years of age or older * experiencing persistent symptoms of brain fog/cognitive impairment beyond 3 months of covid-19 infection that are not explained by an alternative diagnosis exclusion criteria: * not t-vns compatible (e.g. pacemaker implants) * not mri compatible (e.g. metal implants, claustrophobia) * currently pregnant * long covid without cognitive impairment * history of neurological conditions prior to covid-19 infection

Keywords: long covid post covid-19 syndrome covid long-haulers brain fog anosmia/hyposmia neurological symptoms eeg mri genetics inflammation transcutaneous vagus nerve stimulation fatigue anxiety depression cognitive impairment
safety and efficacy of ziprasidone in children and adolescents with bipolar i disorder (manic or mixed) (protocol a1281196)

Conditions: Bipolar Disorder

Summary: the purpose of this study is to determine if flexibly-dosed ziprasidone is safe and effective for the treatment of children and adolescents (ages 10-17) with bipolar l disorder (manic or mixed).


Eligibility criteria:
inclusion criteria: * diagnostic and statistical manual of mental disorders (dsm) iv criteria for bipolar i disorder (manic or mixed) * at the screening and baseline visits, subjects must have a young mania rating scale (ymrs) score of at least 17. * the subject must have a body mass index (bmi) z score between -1.65 and +2.00, inclusive exclusion criteria: * imminent risk of suicide or homicide, as judged by the site investigator * any history of serious or unstable illness * risk for prolonged qt

Keywords: pediatric bipolar
effect of thermal stimulation for lower extremity movement and function in patients with stroke

Conditions: Stroke

Summary: the thermal stimulation have been proven effective in upper extremity of stroke patients. therefore, this study explored the efficacy of thermal stimulation in lower extremity of stroke patients.

there are two groups of stroke patients (onset \> 3 months) in this study. the independent factor is temperature of the alternated heat and cold applying.

Eligibility criteria:
the inclusive criteria: * first-ever stroke * stroke onset \> 3 months and \< 3 years before the study enrollment * unilateral hemiplegia * ability to sit on a chair \> 30 minutes independently * able to follow verbal instructions * age between 18 y/o and 80 y/o * be willing to participate in this study and gave their informed consent the exclusive criteria: * skin disease, skin injuries, burns, or fresh scars over the ts application area * contraindication of ice or heat application * speech disorder or global aphasia * musculoskeletal or cardiac disorders that could potentially interfere * diabetic history or sensory impairment attributable to neuropathy.

Keywords: thermal stimulation lower extremity temperature efficacy
pretreatment with sumatriptan on cilostazol induced headache in healthy volunteers

Conditions: Migraine

Summary: to develop a pragmatic migraine model the investigators will induce headache in healthy volunteers with a phosphodiesterase inhibitor (cilostazol). the participants will be pre-treated with sumatriptan. if the headache responds to sumatriptan, the model can be used to test new drug candidates.

there remains a great need for more effective anti-migraine drugs with fewer side effects. human experimental models are valuable in early phase development of new anti-migraine drugs but useful models have not yet been developed. the investigators' group has shown that cilostazol, a phosphodiesterase inhibitor induce headache/migraine in both healthy volunteers and in patients with migraine without aura (mo). to validate cilostazol as a model, the headache must respond to specific migraine treatment with sumatriptan. hypothesis: cilostazol induces a migraine-like headache in healthy subjects. the induced headache can be pre-treated with a specific anti-migraine drug; sumatriptan. aim: developing a pragmatic and valid model for the testing of new anti-migraine drugs.

Eligibility criteria:
inclusion criteria: healthy subjects of both sexes age 18-60 years weight 50-95 kg. females were requested to use effective contraception. exclusion criteria: any type of headache (except episodic tension-type headache \< 1 day per week) serious somatic or psychiatric disease pregnancy intake of daily medication (except oral contraceptives).
risk factors and biomarkers for post-tuberculosis lung damage

Conditions: Pulmonary TB

Summary: this prospective study aims to determine the incidence of post-tuberculosis lung damage (ptld), examine trends in the changes in lung function, and investigate the impact of smoking and other factors on respiratory symptoms, lung function, and chest ct findings, which will aid in the development of prognostic and therapeutic strategies for ptld.

introduction: post-tuberculosis lung damage (ptld) refers to residual pulmonary impairment following the completion of tuberculosis (tb) treatment, characterized by persistent respiratory symptoms and abnormal pulmonary function. the risk factors and biomarkers for ptld have been scarcely investigated. additionally, it remains unclear whether and to what extent cigarette smoking affects ptld in patients with tb. methods and analysis: this prospective observational study will enroll 400 adult male ever-smoker or never-smoker patients aged 25-60 years, with newly confirmed active tb between 2022 and 2024 from the department of respiratory and critical care medicine at peking university third hospital and the tuberculosis department at beijing geriatric hospital. baseline data (age, smoking history, and smoking pack-years), clinical symptoms, lung functions, and chest ct (computed tomography) findings will be prospectively collected. respiratory questionnaires, lung function measurements, and chest ct examinations will be completed during follow-up visits at 6 months after the initiation of tb treatment, immediately at the completion of tb treatment, and at 1 year, 2 years, and 3 years after the completion of tb treatment. peripheral blood samples will be obtained at baseline to measure inflammatory mediators and cytokines in serum. the collected data will be analyzed to determine the incidence of and factors/biomarkers for ptld after tb treatment.

Eligibility criteria:
inclusion criteria: male patients aged 25-60 years newly diagnosed with active pulmonary tb. exclusion criteria: 1. patients with positive sputum smear or tb culture results; 2. human immunodeficiency virus-positive patients; 3. patients infected with multidrug-resistant tb; 4. patients with malignant neoplasms (e.g., lung cancer) or severe cardiovascular and cerebrovascular diseases; 5. non-compliant patients who were unable to complete the lung function tests; 6. patients without lung parenchymal destruction (such as tuberculous pleurisy). -

Keywords: post-tuberculosis lung damage cigarette smoking
follow up of radiofrequency maze in mitral patients

Conditions: Atrial Fibrillation

Summary: the present study aimed at evaluating mid-term results of radiofrequency modified maze procedure in mitral patients in terms of sinus rhythm and atrial contractility restoration

atrial fibrillation presents with different frequencies in patients affected by structural heart diseases requiring surgery, showing a peak incidence of up to 60-80% in mitral subjects. it causes an increased risk of systemic embolism, cardiac failure development and higher limitations due to dyspnoea and fatigue on exercise. cox-maze technique for surgical atrial fibrillation treatment was first used in 1987 and suffered lots of modifications since then. nowadays, most centers have replaced the "cut and sew" technique by other methods using several power sources to achieve the same target in a much easier way. one of the alternative energy source currently used is radiofrequency ablation which has been demonstrated to be a simple, safe and reproducible procedure with an acceptable success rate in terms of sinus rhythm restoration. however, organized atrial activity (sinus rhythm on surface electrocardiogram) is not always accompanied by an effective mechanical atrial contraction, whose restoration represents one of the original maze objective. atrial contraction is effective when a waves are found in tricuspid and/or mitral transvalvular flow using doppler echocardiography, allowing the patient to fully profit from hemodynamic and clinical advantages of an organized atrial contraction. predictive factors of atrial contractility recovery and, more widely, of sinus rhythm achievement after modified maze procedures have been investigated, but, at our knowledge, a parallel deep analysis and comparison of possible determinants of both surgical ablation goals is still lacking. in the present study, the investigators describe mid-term results of concomitant modified radiofrequency maze in a large homogeneous population of mitral patients, focusing onto common predictors of sinus rhythm and atrial contractility restoring, their time course appearance and interrelation.

Eligibility criteria:
inclusion criteria: * patients affected by atrial fibrillation undergoing mitral valve surgery exclusion criteria: * other cardiac procedures in addition to mitral valve surgery
clinical trial to study the anti-scarring effect of cicatricell

Conditions: Surgical Incisions

Summary: this study tries to prove that cicatricell cream significantly reduces scarring with better wound appearance as compared to no treatment.

at 1st post operative follow up visit, surgical incision(s) will be assessed for healing, after the sutures/staples/steri-strips are removed. to be included in the study the incision must be 5cm or greater. and bilateral incisions as in bilateral mastectomy can be included. the incisions will be divided into two sections, using an imaginary line between top and bottom, or left and right. one side of the imaginary line will have cicatricell cream applied 2 times a day for a minimum of 8 weeks and a maximum 6months. the other side of the imaginary line will remain untreated. in the case of a bilateral incision, as in bilateral breast mastectomy or aaa incisions in the groins, the cream will be applied to one entire incision and the 2nd incision will be untreated. the incision(s) will be its own control group. at the end of the treatment phase the incision(s) will be assessed again to compare the healing.

Eligibility criteria:
inclusion criteria: * signed irb approved, written informed consent. * patient from 18 to 60 years of age. * patient who recently underwent a surgery involving linear surgical skin incisions of 5cm or more or patients with two exactly symmetrical separate incisions like bilateral inguinal hernia repair or bilateral mastectomy, ct surgery patients will be included. exclusion criteria: * known skin allergies.
impact of asthma exacerbations

Conditions: Asthma Attack

Summary: the purpose of the study is to gain a deeper understanding of the impact of asthma attacks on the lives of patients who experience them. this will help us to describe the true extent of the impact of asthma attacks on factors of importance to patients which have not previously been well described, including the psychological, social, financial and emotional burden of asthma attacks. additionally, it is hoped that detailed questioning regarding features of asthma attacks from a patient perspective will improve our understanding of patient recognition of attacks, consistency of certain features of attacks and patient views regarding preventative strategies for attacks. patient experiences of asthma attacks are poorly described in previous research. hence this work is expected to provide useful insights into these experiences which will contribute to improvements in detecting, treating and preventing asthma attacks. the study will consist of a one-off interview lasting about 45 minutes with patients who have recently had asthma attacks. we plan to recruit patients for the study from an outpatient clinic for those who have had a recent attack or from a register of patients who have volunteered for future asthma research studies. the interviews will take place in person at the respiratory research unit at the nottingham city hospital or over the telephone depending on patient preference.


Eligibility criteria:
inclusion criteria: * adults with previous clinician diagnosis of asthma (16 years and above) * recent (≤4 weeks) asthma attack for which patient received ≥3 days of systemic corticosteroid treatment exclusion criteria: * anyone under the age of 16 years. * anyone unable to speak or understand english.
phase 2 trial of rgx-314 in adults with center involved - diabetic macular edema (ci - dme)

Conditions: Diabetic Macular Edema

Summary: phase 2 open label, randomized, active controlled, dose-ranging trial in adults with center involved - diabetic macular edema (ci - dme)

this phase 2 trial is an open label, randomized, active controlled, dose-ranging trial to allow for preliminary safety and efficacy data on subretinal (sr) delivery of rgx-314 in participants with ci - dme

Eligibility criteria:
inclusion criteria: * type i or type ii diabetes mellitus with center involving diabetic macular edema with previous treatment * hba1c ≤12% * bcva in study eye 78 to 25 etdrs letters (\~20/32 to 20/320) at screening * decreased visual acuity attributable primarily due to ci - dme * demonstrate clinical response to aflibercept injection in the study eye * provide written informed consent exclusion criteria: * women of childbearing potential * neovascularization in the study eye from a cause other than dr * evidence in the study eye of optic nerve pallor on clinical examination * history of pan retinal photocoagulation in the study eye * any concurrent ocular condition in the study eye other than ci-dme that could require surgical intervention within 6 months or any condition in the study eye that may increase the risk to the participant, require either medical or surgical intervention during the study to prevent or treat vision loss, or interfere with the study procedures or assessments * presence of an implant in the study eye at screening (excluding intraocular lens) * any condition in the investigator's opinion that could limit va improvement in the study eye * active or history of glaucoma, steroid response, or ocular hypertension * any prior intravitreal steroid injection in the study eye within 6 months prior to screening, administration in the study eye of ozudrex® within 12 months prior to screening, or administration in the study eye if iluven® within 36 months prior to screening * diabetic macular edema diagnosis ≥ 7 years * history of chronic renal failure requiring dialysis or kidney transplant * participation in any other gene therapy study or receipt of any investigational product within 30 days prior to enrollment or 5 half-lives of the investigational product, whichever is longer, or any plans to use an investigational product within 6 months following enrollment note: other inclusion/exclusion criteria apply

Keywords: diabetic macular edema gene therapy
antiviral t lymphocyte immunity during acute covid-19 infection

Conditions: Corona Virus Infection

Summary: the sars-cov-2 (covid-19) infection is causing a global pandemic and a major health crisis in france. immunity is the body's ability to defend itself against infectious agents such as viruses. the progressive acquisition by a large part of the population of immunity to defend itself against the covid-19 virus is one of the main mechanisms by which a resolution of this pandemic is hoped for. recovery from infection and protection from the virus is likely to depend on the development of antibodies (proteins produced by the body to neutralize infectious agents) and t-cells (a type of white blood cell in the immune system) that can stop the virus from multiplying and killing it. to date, the way and speed at which the t-lymphocytes active against the virus appear are not known. the development of biological tests to detect t-cells active against the virus in the blood of infected patients is therefore necessary. in this context, we propose you to participate in a study that will study the immune system's response against the sars-cov-2 virus during and after covid-19 infection.


Eligibility criteria:
inclusion criteria: * patient with an acute sars-cov-2 infection, confirmed by pcr or typical ct images, requiring hospitalization in a covid unit at the rouen university hospital (pneumonic form requiring oxygen therapy \< 4 l/min.) * rouen university hospital staff free of any symptomatology compatible with an sars-cov-2 infection (fever, cough, fatigue, loss of taste, loss of smell) since february 1, 2020 * age ≥ 18 years old * adult patient who has read and understood the information letter and signed the consent form * affiliation to a social security scheme exclusion criteria: * patient with pcr-confirmed sars-cov-2 infection and hospitalized in intensive care units (acute respiratory distress and/or organ failure, whose pathogenesis may differ from the more frequently described forms with secondary aggravation (5)). * patient with pcr-confirmed but non-hospitalized sars-cov-2 infection (non-acute form, managed by confinement) * a person participating in a therapeutic trial that may interfere with the procedures being investigated, including lymphocyte response prior to d+56±14 days. * known pregnancy * person deprived of liberty by an administrative or judicial decision or person placed under judicial protection / subtutorship or guardianship * staff at the rouen university hospital with sars-cov-2 infection confirmed by pcr and/or typical scan images during the epidemic period. * hospital staff who were exposed to the virus (working in a covid unit)
investigating long-term health effects and complications in covid-19 recoveries

Conditions: COVID-19 Patients

Summary: clarify the incidence of functional impairments in cured covid-19 patients and identify influencing factors. build a multi-omics database for covid-19 patients in the recovery period to elucidate the biological biomarkers and targets associated with functional impairments. comprehensive exploration of the long-term prognosis, complications, sequelae, and risk factors of covid-19 patients after omicron infection, as well as their immune characteristics. compare the impact of different strains of the covid-19 virus on prognosis and immune response. develop comprehensive rehabilitation intervention strategies for covid-19 patients with functional impairments and evaluate the impact of different intervention methods on their prognosis. based on clinical data, multi-omics data, and precise rehabilitation assessment data, construct predictive models for prognosis and rehabilitation effectiveness in covid-19, providing scientific evidence for the implementation of effective covid-19 rehabilitation measures.


Eligibility criteria:
inclusion criteria: 1. meets the diagnostic criteria for confirmed cases according to the "diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 10)"; 2. the participant or the authorized representative understands the entire purpose of the study, voluntarily participates in the research, and signs an informed consent form, ensuring that they can complete regular assessments at the relevant participating units and receive necessary rehabilitation treatment as required; 3. agrees to the researcher's collection of their peripheral blood samples, saliva samples, and urine samples for the needs of the study. exclusion criteria: 1. women who are pregnant or breastfeeding; 2. individuals with mental disorders that affect normal communication; 3. those who refuse to participate in regular assessments and rehabilitation treatments; 4. individuals who decline to provide specimens required for the study.
developing a clinical prediction model for adverse outcomes in percutaneous trigeminal ganglion balloon compression

Conditions: Trigeminal Neuralgia (TN)

Summary: this clinical study aims to investigate adverse outcomes following percutaneous balloon compression (pbc) of the trigeminal ganglion, establish a predictive model, and assess the probability of postoperative complications.the main question it aims to answer is: 1. what factors are associated with adverse postoperative outcomes? 2. what is the occurrence probability of different types of adverse outcomes? the study will record patients' demographic and clinical characteristics, laboratory test results, and conduct follow-ups at 3, 6, and 12 months postoperatively.


Eligibility criteria:
inclusion criteria: 1. diagnosed with primary trigeminal neuralgia and underwent pbcg at the pain department of affiliated hospital of nantong university 2. age ≥18 years 3. willing to complete postoperative follow-up exclusion criteria: 1. secondary trigeminal neuralgia (e.g., tumor compression, multiple sclerosis) 2. previous interventional treatments for trigeminal neuralgia 3. incomplete follow-up data 4. general anesthesia contraindications or significant dysfunction of major organs (cardiac, pulmonary, hepatic, renal) or severe neurological impairment

Keywords: trigeminal neuralgia pcgg poor prognosis clinical prediction model